<- Go Home
Nautilus Biotechnology, Inc.
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Market Cap
$214.7M
Volume
82.7K
Cash and Equivalents
$4.4M
EBITDA
-$79.4M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$3.09
52 Week Low
$1.56
Dividend
N/A
Price / Book Value
0.96
Price / Earnings
-3.05
Price / Tangible Book Value
0.96
Enterprise Value
$105.7M
Enterprise Value / EBITDA
-1.51
Operating Income
-$81.5M
Return on Equity
28.04%
Return on Assets
-17.62
Cash and Short Term Investments
$140.6M
Debt
$31.6M
Equity
$223.4M
Revenue
N/A
Unlevered FCF
-$35.0M
Sector
Life Sciences Tools and Services
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium